Scientists have identified a specific mechanism linking the gut microbiome to age-related cognitive decline. In a study using mice, researchers discovered that as the animals aged, their gut microbiome changed, leading to an accumulation of a bacterium called *Parabacteroides goldsteinii*. This bacterium produces compounds that activate an inflammatory receptor (GPR84) on peripheral immune cells. This inflammation, in turn, impairs the function of the vagus nerve, a critical communication highway connecting the gut to the brain. The weakened signal from the gut resulted in reduced neuronal activity in the hippocampus, the brain's memory center, leading to memory deficits in the aged mice. Crucially, the researchers were able to reverse this memory loss by intervening at several points in the pathway: using bacteriophages to target the specific bacteria, chemically blocking the GPR84 receptor, or directly stimulating the vagus nerve.
In a significant setback for Alzheimer's research, two large-scale clinical trials found that oral semaglutide, the active ingredient in weight-loss drugs like Rybelsus, did not slow the progression of early-stage Alzheimer's disease. The evoke and evoke+ trials were Phase 3, randomized, placebo-controlled studies involving 3,808 participants aged 55-85 with confirmed mild cognitive impairment or mild dementia. Participants received either a daily 14 mg dose of semaglutide or a placebo for up to three years. The primary measure of efficacy was the change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score, a standard tool for assessing cognitive and functional decline. After two years, researchers found no meaningful difference in decline between the semaglutide and placebo groups. Due to the lack of efficacy, the trials were discontinued. The drug's safety profile was consistent with its use in other conditions like diabetes and obesity.
The economic burden of brain health disorders extends far beyond hospital bills, with a new study quantifying the immense cost of unpaid care provided by family and friends. In a global modeling study analyzing data from 204 countries, researchers estimated that in 2021, informal caregivers provided 9.4 billion hours of care for individuals with one of 24 brain disorders. This staggering amount of time translated into US$1.7 trillion in forgone earnings for the caregivers. The study, which tracked trends from 2000 to 2021, also found that this burden is steadily growing, with the hours of informal care increasing by an average of 3.2% per year. While stroke was the condition requiring the most hours of care, dementia was responsible for the largest financial impact in terms of lost income for caregivers.
A 12-month RCT of 160 patients with early-stage Alzheimer's disease found that supervised aerobic exercise (3 sessions per week, 45 minutes each) significantly slowed cognitive decline, preserved hippocampal volume, and increased serum BDNF levels compared to a stretching control group. The exercise group showed 35% less decline on standardized cognitive assessments.